Tag Archives: American Psychiatric Association

The business of ADHD

As the DSM-V looms closer to becoming a reality, I can’t help but think of words from the man who chaired the committee for the DSM-IV. Allen Frances, M.D., wrote in the in the LA Times:

As chairman of the task force that created the current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), which came out in 1994, I learned from painful experience how small changes in the definition of mental disorders can create huge, unintended consequences.

Our panel tried hard to be conservative and careful but inadvertently contributed to three false ‘epidemics’ – attention deficit disorder, autism and childhood bipolar disorder. Clearly, our net was cast too wide and captured many ‘patients’ who might have been far better off never entering the mental health system.

American Psychiatric Association Stunned Again with Ghostwriting Controversy

Like an aging, punch drunk fighter struggling through the twelfth round, the American Psychiatric Association (APA) can’t seem to slip the punches coming its direction. Last week, a host of blogs went after them for refusing to print a letter written by three academics that was critical of a medical textbook the APA published with help from the ghostwriting company Scientific Therapeutics Information (STI).

The letter criticized the APA for failing to publish records that explain the provenance of the textbook, including drafts, contracts with STI and/or GlaxoSmithKline, and any communications regarding editing. The text’s purported authors are Dr. Charles Nemeroff of the University of Miami and Dr. Alan Schatzberg of Stanford University.

As The New York Times reported, the textbook was funded by GlaxoSmithKline. Author and blogger Dr. Danny Carlat reviewed the book and wrote that it read like “an advertisement for Paxil.”

Yesterday, a writer over at MIWatch landed a blistering combination on the APA. When she poked them for a response, the APA covered up and peeked back through their gloves. “The APA’s official response has been unconvincing,” she jabbed.

She then landed a solid uppercut.

American Psychiatric Association’s Ghost Written (Allegedly Pharma Funded) Book Magically ‘Disappears’

File this under The Case of The Missing Book. When last seen, Scientific Therapeutics Information was at the center of an ongoing controversy over an allegedly ghostwritten book – yes, an entire book – that was published in 1999 by the American Psychiatric Association. Funding came from a grant provided by SmithKline Beecham, which is now part of GlaxoSmithKline (back story).

The listed co-authors were Charles Nemeroff, who chairs the psychiatry department at the University of Miami medical school, and Alan Schatzberg, who until recently chaired the psychiatry department at the Stanford University School of Medicine. Both men were at the center of a long-running probe by the US Senate Finance Committee into undisclosed conflicts of interest among academic researchers. They were also regular speakers for Glaxo, which makes the Paxil antidepressant

American Psychiatric Association Slammed by Disease Mongering Parody Featuring Instant Disease Generation Engine

The American Psychiatric Association is under fire today by an independent health news site’s launch of the “Disease Mongering Engine” – an online tool that allows users to instantly generate disorders, dysfunctions and syndromes that sound real, but aren’t. Available at www.NewsTarget.com, the Disease Mongering Engine was created by Mike Adams, a vocal critic of modern psychiatric medicine and its practice of labeling healthy people with fictitious diseases, then over-medicating them with patented pharmaceuticals.

“Modern psychiatry has lost its way and has now become a marketing branch of Big Pharma,” Adams said. “Convincing healthy people that they’re diseased, then harming them with unsafe chemical medications, is not a legitimate approach to health and healing.” Diseases ranging from ADHD to Social Anxiety Disorder were “invented” by drug companies and psychiatrists, Adams says, as a way to generate billions of dollars in profits by selling treatment drugs and services to people who don’t need them.

Psychiatric drug industry driven by wealth and stealth, not mental health

Drug company corporate websites tell us of their integrity and utmost commitment to people’s health and well-being. The American Psychiatric Association’s website begins with “Healthy Minds. Healthy Lives” and asserts the “highest ethical standards of professional conduct.” Yet a mountain of evidence points to an entirely different picture. Most recently, thirty-eight state attorneys won a $68.5 million settlement with pharmaceutical titan AstraZeneca for unlawful marketing of antipsychotic Seroquel for unapproved use. These states also charged this company with failing to disclose the drug’s harmful side effects and concealing negative information about its safety and efficacy. “The company’s illegal practices put our most vulnerable populations at risk, including children and older patients with dementia and other debilitating diseases,” states Illinois Attorney General. U.S. sales of Seroquel brought in $5.3 billion for AstraZeneca last year.